The present invention relates to a composition of matter comprising novel
prostaglandin E2 receptor antagonists, and their use in treatments for
regulating the fluid filtration in the kidney, preventing bone mineral
loss in osteoporosis and dental disease and additionally, closure of
ductus arteriosus (DA) in premature infants or fetal animals.
Additionally, the compositions include linear peptides, peptide analogs,
and peptidomimetics.